seltorexant + itraconazole

**Seltorexant + itraconazole** is a combination of seltorexant, a small-molecule selective orexin receptor type-2 antagonist under development primarily for the treatment of major depressive disorder and insomnia, and itraconazole, an established antifungal agent that is a potent inhibitor of the CYP3A4 enzyme. Seltorexant blocks the orexin OX2 receptor, reducing arousal and promoting sleep, and is being investigated for both antidepressant and sleep-promoting effects[1][3][5][7]. Itraconazole, while an antifungal, is sometimes used in pharmacokinetic studies to characterize the drug interaction potential via inhibition of CYP3A4, which is the main metabolic pathway for seltorexant[3]. The combination may be studied in a pharmacokinetic context to assess the impact of CYP3A4 inhibition on seltorexant’s metabolism, exposure, and safety profile, not as a routine therapeutic combination.